Drug Development Challenges in Pharmaceuticals: R&D for Long COVID is Collapsing
Understanding the Collapse of R&D for Long COVID
Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with additional funds. They now find themselves in the same position as many previous pharmaceutical investments, where the lack of research funding stifles innovation.
Key Issues in Drug Development
- Inadequate funding impacting long-term research strategies.
- Perceived risks in investing in long COVID treatments.
- The need for stronger policy advocacy to secure funds.
Long COVID and Chronic Illness
The ongoing challenges faced by researchers point to a broader issue within the pharmaceuticals sector regarding long COVID and related chronic illnesses. With effective business policies yet to be established, the research landscape remains precarious.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.